Apyx Medical reports Q1 EPS (10c), consensus (12c)

Reports Q1 revenue $9.43M, consensus $9.39M. “We have made steady progress executing against our commercial strategy to position Apyx as the leader in surgical aesthetics. We believe Renuvion, which is the only FDA-cleared device for use after liposuction, is positioned to be the standard-of-care for the rapidly growing patient population on GLP-1 drugs that choose to address their loose skin post-weight loss. This is an exciting new opportunity within the industry that we believe offers our company tremendous opportunities for future growth. As a sign of the system’s increasing industry awareness, Renuvion was just named this year’s NewBeauty Award winner in the ‘Best Minimally Invasive Skin Tightener’ category,” said Charlie Goodwin, President and Chief Executive Officer. “Building on the growing success of Renuvion, we are planning the highly anticipated launch of the AYON Body Contouring System in the second half of this year, pending FDA clearance. This new system seamlessly integrates Renuvion, ultrasound-assisted liposuction, power-assisted liposuction, infiltration, aspiration, electrocoagulation, and closed loop contouring into a single, streamlined device that is capable of being the heart of any aesthetic surgeon’s operating room. I am happy to report that we offered surgeons an early look at this revolutionary all-in-one system at the Aesthetic MEET in March and the feedback we received was overwhelmingly positive.”